Results 251 to 260 of about 1,905,493 (317)
Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree +9 more
wiley +1 more source
Rethinking Trust in Synthetic Health Data: Lessons From 7 European Research Initiatives. [PDF]
Declerck J +17 more
europepmc +1 more source
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw +5 more
wiley +1 more source
Scenario-Driven Synthetic Data Generation Framework for Visual Perception Evaluation Under Adverse Driving Conditions. [PDF]
Xu W, Gruyer D, Duminil A, Ieng SS.
europepmc +1 more source
Timbre Encoding in the Inferior Colliculus. [PDF]
Fritzinger JB, Carney LH.
europepmc +1 more source
Editorial: Biomolecule production in plant synthetic biology. [PDF]
Lee S, Kwon M.
europepmc +1 more source
Integrating Genome-Scale Metabolic Modeling with Machine Learning Improves Gene Essentiality Prediction in Triple-Negative Breast Cancer. [PDF]
Kim BK, Gu C, Farh ME, Ryu JY.
europepmc +1 more source
GLiNER-BioMed: a suite of efficient models for open biomedical named entity recognition. [PDF]
Yazdani A, Stepanov I, Teodoro D.
europepmc +1 more source

